Kawa SM, Larsen SB, Helgstrand JT, et al. - By performing this systematic review, researchers assessed the risk of prostate cancer-specific mortality (PCSM) after initial negative systematic transrectal ultrasound-guided (TRUS) prostate biopsies. By exploring PubMed and Embase, studies examining PCSM after initial negative TRUS biopsies were selected. Experts found four eligible studies. They noted that the risk of PCSM after initial negative biopsies was inquired in only a few studies and all studies involved patients prior to the era of MRI of the prostate. Findings revealed low risk of PCSM after initial negative TRUS biopsies. Results also showed that prognostic information is afforded by the level of prostate-specific antigen prior to biopsies. This may be taken into account when suggesting patients regarding the requirement for further diagnostic assessment.